. Author manuscript; available in PMC: 2019 Dec 15.

Published in final edited form as: J Acquir Immune Defic Syndr. 2018 Dec 15;79(5):605–611. doi: 10.1097/QAI.0000000000001862

Table 1.

Timeline of Interventions and Guidelines

		2012						2013					2014
		Jan-Mar	Apr-Jun	Jul-Sep	Oct-Dec			Jan-Mar	Apr-Jun	Jul-Sep	Oct-Dec		Jan-Mar	Apr-Jun	Jul-Sep	Oct-Dec
Data Collection	TB REACH	Intervention Study Period: Jan – Oct 2012				Follow-up Period^*: Nov 2012-Jun 2013
Data Collection	MENTORS						Baseline Study Period: Jan-Sept 2013				Intervention Study Period: Oct 2013- Jun 2014				Follow-up Period^*: Jul 2014-Mar 2015
Guidelines	ART	Ending Nov 2013 CD4 count < 250 cells/mm3 or signs of stage 4 HIV: initiate ART after 2 weeks of TB treatment CD4 count was above 250 cells/mm3: initiate ART after completion of TB treatment										Starting Dec 2013 CD4 count < 50 cells/mm3: initiate ART after 2 weeks of TB treatment CD4 count > 50 cells/mm3: initiate ART after 8 weeks of TB treatment
Guidelines	TB	Ending Nov 2013 8-month regimen: 2 months HRZE, 6 months HE										Starting Dec 2013 6-month regimen: 2 months HRZE, 4 months HR

Outcomes for patients who started treatment during the intervention study period were collected during the follow-up period.

Abbreviations: Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Ethambutol (E)